Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.58 |
| ▸ | HTR3B | O95264 | 1/20 | 0.58 |
| ▸ | HTR3A | P46098 | 1/20 | 0.58 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.58 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.45 |
| ▸ | NOS3 | P29474 | 2/20 | 0.44 |
| ▸ | NOS1 | P29475 | 2/20 | 0.44 |
| ▸ | NOS2 | P35228 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3284038 | 1.00 | HTR3E (0.58) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL670198 | 0.93 | ALDH1A1 (0.57) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL670197 | 0.93 | ALDH1A1 (0.57) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL12669320 | 0.85 | MEN1 (0.59) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL148825 | 0.85 | HTR3E (0.46) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL148824 | 0.85 | HTR3E (0.46) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL32679882 | 0.85 | MEN1 (0.59) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL14603036 | 0.83 | ADRA2A (0.47) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL5317521 | 0.82 | HTR3E (0.47) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL12613288 | 0.82 | MAOA (0.69) | HTR3EHTR3BHTR3AHTR3DHTR3C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1787631-A1 | New dye precursor combinations | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 2007-05-23 | — | — | EP | claimed |
| US-10400024-B2 | Cleavage and exchange of major histocompatibility complex ligands employing azobenzene-containing peptides | SANQUIN REAGENTS B.V. (NL) | 2019-09-03 | — | — | US | disclosed |
| US-20170101459-A1 | CLEAVAGE AND EXCHANGE OF MAJOR HISTOCOMPATIBILITY COMPLEX LIGANDS EMPLOYING AZOBENZENE-CONTAINING PEPTIDES | STICHTING SANQUIN BLOEDVOORZIENING (NL) | 2017-04-13 | — | — | US | disclosed |
| EP-1787631-A1 | New dye precursor combinations | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 2007-05-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170101459-A1 | CLEAVAGE AND EXCHANGE OF MAJOR HISTOCOMPATIBILITY COMPLEX LIGANDS EMPLOYING AZOBENZENE-CONTAINING PEPTIDES | CD74, HLA-B, MICA | HTR3E 3992/4885HTR3B 2952/4885HTR3A 4169/4885 |
| US-10400024-B2 | Cleavage and exchange of major histocompatibility complex ligands employing azobenzene-containing peptides | CD74, HLA-B, MICA | HTR3E 3992/4885HTR3B 2952/4885HTR3A 4169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.